[HTML][HTML] Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
G Schernthaner, N Shehadeh, AS Ametov… - Cardiovascular …, 2020 - Springer
The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …
[PDF][PDF] Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
G Schernthaner, N Shehadeh, AS Ametov… - 2020 - scholar.archive.org
The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
G Schernthaner, N Shehadeh… - Cardiovascular …, 2020 - search.proquest.com
The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.
G Schernthaner, N Shehadeh, AS Ametov… - Cardiovascular …, 2020 - sonar.ch
English The disclosure of proven cardiorenal benefits with certain antidiabetic agents was
supposed to herald a new era in the management of type 2 diabetes (T2D), especially for …
supposed to herald a new era in the management of type 2 diabetes (T2D), especially for …
[PDF][PDF] Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
G Schernthaner, N Shehadeh, AS Ametov… - 2020 - core.ac.uk
The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …
[PDF][PDF] Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
G Schernthaner, N Shehadeh, AS Ametov… - 2020 - science.rsu.lv
The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …
[PDF][PDF] Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
G Schernthaner, N Shehadeh, AS Ametov… - 2020 - academia.edu
The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …
[引用][C] Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
G Schernthaner, N Shehadeh, AS Ametov… - Cardiovascular …, 2020 - elibrary.ru
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
G Schernthaner, N Shehadeh… - Cardiovascular …, 2020 - pubmed.ncbi.nlm.nih.gov
The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …
[PDF][PDF] Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
G Schernthaner, N Shehadeh, AS Ametov… - 2020 - researchgate.net
The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …